SCHEMBL4868424

SCHEMBL4868424

Cc1nc(C)c(-c2ccc(-c3c(C4CCCCC4)c4sc(C(=O)O)cc4n3CC(=O)N3CCC(N4CCOCC4)CC3)cc2)s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CBX7 O95931 2/20 0.38
CDYL2 Q8N8U2 2/20 0.38
CDYL Q9Y232 2/20 0.38
CDY1; CDY1B Q9Y6F8 2/20 0.38
TSHR P16473 2/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
PDE7A Q13946 2/20 0.35
ACHE P22303 1/20 0.35
TP53 P04637 1/20 0.35
BRD4 O60885 1/20 0.35
CREBBP Q92793 1/20 0.35
GSK3B P49841 1/20 0.35
DYRK1A Q13627 1/20 0.35
KDM4E B2RXH2 3/20 0.34
LMNA P02545 1/20 0.34
ALDH1A1 P00352 3/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TLR9 Q9NR96 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4872850 0.94 BRD4 (0.39) TSHRBRD4CREBBPKDM4EALDH1A1
SCHEMBL4874701 0.90 TP53 (0.36) CBX7CDYL2CDYLCDY1; CDY1BTSHR
SCHEMBL4868434 0.88 CBX7 (0.42) CBX7CDYL2CDYLCDY1; CDY1BTSHR
SCHEMBL4877273 0.85 TP53 (0.40) CBX7CDYL2CDYLCDY1; CDY1BTSHR
SCHEMBL3931408 0.84 KCNH2 (0.37) GAATP53BRD4CREBBPMAPT
SCHEMBL4875180 0.84 KCNH2 (0.38) GAATP53BRD4CREBBPMAPT
SCHEMBL2996624 0.84 MAPK1 (0.44) POLBTP53BRD4CREBBPKDM4E
SCHEMBL4875343 0.81 BRD4 (0.33) GAABRD4CREBBPTLR9TLR8
SCHEMBL4877126 0.81 CBX7 (0.37) CBX7CDYL2CDYLCDY1; CDY1BTSHR
SCHEMBL2988730 0.81 MAPK1 (0.43) CBX7CDYL2CDYLCDY1; CDY1BTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051384-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 CBX7 2500/4885CDYL2 4283/4885CDYL 4218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.